Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative

Journal of Bone and Mineral Research

Volumn 28, Issue 9, 2013, Pages 2043-2048

  Passarelli, Michael N ^a,b   Newcomb, Polly A ^a,b   Lacroix, Andrea Z ^a,b   Lane, Dorothy S ^c   Ho, Gloria Y F ^d   Chlebowski, Rowan T ^e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

BISPHOSPHONATES; COLORECTAL CANCER; POSTMENOPAUSAL WOMEN; WOMEN'S HEALTH INITIATIVE

Indexed keywords

ALENDRONIC ACID; CALCIUM; ESTROGEN; ETIDRONIC ACID; GESTAGEN; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL POLYP; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OCCULT BLOOD TEST; POSTMENOPAUSE; PROBABILITY; RISK REDUCTION; SIGMOIDOSCOPY; TREATMENT DURATION; WOMEN'S HEALTH;

BISPHOSPHONATES; COLORECTAL CANCER; POSTMENOPAUSAL WOMEN; WOMEN'S HEALTH INITIATIVE;

ADMINISTRATION, ORAL; AGED; COLORECTAL NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RISK FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 84882580219     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1930     Document Type: Article

References (20)

1. Whitaker M, Guo J, Kehoe T, Benson G., Bisphosphonates for osteoporosis-where do we go from here ? N Engl J Med. 2012; 366: 2048-51.
2. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ., Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296: 235-42.
3. Neville-Webbe HL, Holen I, Coleman RE., The anti-tumour activity of bisphosphonates. Cancer Treat Rev. 2002; 28: 305-19.
4. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G., Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998; 339: 357-63.
5. Newcomb PA, Trentham-Dietz A, Hampton JM., Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 2010; 102: 799-802.
6. Rennert G, Pinchev M, Rennert HS., Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010; 28: 3577-81.
7. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB., Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010; 28: 3582-90.
8. Rennert G, Pinchev M, Rennert HS, Gruber SB., Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol. 2011; 29: 1146-50.
9. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V., Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010; 341: c4444.
10. Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM, Murray LJ., Exposure to oral bisphosphonates and risk of cancer. Int J Cancer. 2012; 131: E717-25.
11. Singh H, Nugent Z, Demers A, Mahmud S, Bernstein C., Exposure to bisphosphonates and risk of colorectal cancer: a population-based nested case-control study. Cancer. 2012; 118: 1236-43.
12. Pazianas M, Abrahamsen B, Eiken P, Eastell R, Russell RG., Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study. Osteoporos Int. 2012; 23: 2693-701.
13. Vestergaard P., Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int. 2011; 89: 434-41.
14. Khalili H, Huang ES, Ogino S, Fuchs CS, Chan AT., A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol. 2012; 30: 3229-33.
15. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998; 19: 61-109.
16. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL., Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003; 13: S5-17.
17. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M., Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003; 13: S122-8.
18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg CL, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33.
19. Anderson GL, Limacher MC, Assaf AR, Bassford T, Beresford SAA, Black HR, Bonds DE, Brunner RL, Brzyski RG, Caan B., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-12.
20. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD, LeBoff MS, Lewis CE, Chen Z, Stefanick ML, Cauley J., Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007; 298: 2389-98.